<DOC>
	<DOCNO>NCT01939951</DOCNO>
	<brief_summary>This study aim find AES ( Activation Energy Serum ) , blend natural mineral , effective safe treatment asthma take 4 week . The efficacy scientifically test symptoms score , questionnaire , breathe blood test .</brief_summary>
	<brief_title>Efficacy Safety Activation Energy Serum ( AES ) Versus Placebo Persistent Asthma .</brief_title>
	<detailed_description>The primary objective study compare overall efficacy safety AES ( Activation Energy Serum ) demonstrate clinically significant improvement morning FEV1 patient mild moderate persistent asthma treat 2 dos AES 4 week compare placebo . The secondary objective evaluate effect AES ) clinical symptom symptom score Asthma Control Questionnaire ( ACQ ) , b ) fractional exhale nitric oxide ( FeNO ) , c ) blood eosinophil count biomarkers , ) quality life Asthma Quality Life Questionnaire ( AQLQ ) .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Patients eligible inclusion study fulfill follow criterion : 1 . Written informed consent must obtain assessment perform 2 . Males females race 18 65 year old time inform consent obtain . 3 . Physician diagnosis asthma , per NIH ( National Institutes Health ) guideline , least 3 month . 4 . Patients prebronchodilator FEV1 ( forced expiratory volume 1 second ) value 40 % 90 % individual predict value screen randomization , value randomization within 15 % screen FEV1 . The result spirometry meet ATS/ERS ( American Thoracic Society/European Respiratory Society ) criteria acceptability repeatability . 6 . Patients demonstrate reversible airway obstruction airways hyper reactivity show either response previous test ( ) within last year . • Reversible airway obstruction define increase ≥12 % ≥200 ml FEV1 patient 's prebronchodilator value litres within 1015 minute inhale total 360 µg albuterol 400 µg salbutamol via MDI ( meter dose inhaler ) ( reversibility test ) . The administration albuterol salbutamol reversibility test within 30 minute prebronchodilator spirometry . 7 . An ACQ ( Asthma Control Questionnaire ) score ≥ 1.5 randomization . 8 . Total daily asthma symptom score &gt; 4 3 7 day Screening Randomization Visit . 9 . A fractional exhaled nitric oxide ( FeNO ) level &gt; 25 ppb 9 . Blood eosinophil count &gt; 200 /mm3 . 1 . Use investigational drug time enrollment , within 30 day 5 half life enrollment , whichever longer . 2 . History hypersensitivity AES product . 3 . History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis . 4 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG ( human chorionic gonadotropin ) laboratory test ( &gt; 5 mIU ( milli international unit ) /mL ) . 6 . Women childbearing potential , defined woman physiologically capable become pregnant , must use effective contraception study 4 day ( 5 halflives ) treatment . Effective contraception define either : Barrier method : c ) Barrier method contraception : Condom Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/vaginal suppository . Spermicides alone barrier method contraception use alone . The following method consider effective barrier method also acceptable : Total abstinence : When line prefer usual lifestyle subject . [ Periodic abstinence ( e.g . calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception ] . Female sterilization : surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation least 6 week take study treatment . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment . Male partner sterilization . [ For female study subject , vasectomise male partner sole partner patient ] Use establish , oral , injected implant hormonal method contraception , intrauterine device ( IUD ) intrauterine system ( IUS ) 7 . Patients serious comorbidities include uncontrolled diabetes ( HbA1c ≥8 % ) , heart failure , cancer , neurodegenerative disease , rheumatoid arthritis autoimmune disease , lung disease include chronic bronchitis , chronic obstructive pulmonary disease emphysema condition characterise eosinophilia pulmonary symptom ( i.e . ChurgStrauss syndrome , allergic bronchopulmonary aspergillosis , eosinophilic pneumonia , etc. ) . 8 . Acute illness asthma start study . 9 . History lifethreatening asthma , include history significant hypercarbia ( pCO2 &gt; 45mmHg ) , prior intubation , respiratory arrest , seizures result asthma . 10 . History alcohol substance abuse . 11 . Patients respiratory tract infection within 2 week screen visit . Patients develop respiratory tract infection screen randomization visit must screen fail , may permit reenroll later date . 12 . Patients hospitalize due asthma , require treatment systemic steroid , within 6 week screen visit . 13 . Patients clinically significant laboratory abnormality ( associate study indication ) screening . 14 . Current smoker exsmokers stop smoke within 6 month prior screen smoke history ≥ 10 pack year . 15 . Patients body mass index ( BMI ) &lt; 17 &gt; 40 kg/m2 . 16 . Patients receive likely require treatment study prohibit asthma relate medication class group list Table 53 . 17 . Patients maintenance immunotherapy either begin immunotherapy regimen clinically relevant change immunotherapy within 1 month prior grant inform consent . Patients stable maintenance immunotherapy least one month prior Visit 1 enrol . 19 . Patients previously randomize study . 20. Who unable perform spirometry , peak flow measurement , fractional exhale nitric oxide , complete patient diary complete questionnaire require protocol . 21 . With medical mental condition , investigator opinion , render patient unable understand nature , scope , possible consequence study . 22. Who unable/unwilling take 7 drop twice per day , unable use inhaler unlikely comply protocol . 23 . Use immunosuppressive medication ( except inhale topical corticosteroid ) within 30 day randomization study . 24 . A positive hepatitis B surface antigen , hepatitis C virus antibody , determine medical history and/or subject 's verbal report . 25 . A positive human immunodeficiency virus test take antiretroviral medication , determine medical history and/or subject 's verbal report . 26 . History known immunodeficiency disorder . 27 . Any condition , opinion investigator , would interfere evaluation investigational product interpretation study result . 28 . Patients , opinion investigator , unsuitable take part study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Persistent</keyword>
</DOC>